FY2025 · ended Dec 31, 2025 · Revenue $51.95M, -18.5% YoY · Filed Feb 5, 2026
Ocular Therapeutix, Inc (OCUL) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $52.0 million and a net loss of $265.9 million. Free cash flow was -$216.9 million. As of Jun 30, 2026 it held $598.6 million in cash and investments and $6.6 million in total debt.
Revenue (TTM)
$52.05M
-8.1% vs year-ago TTM
Net income (TTM)
$-301.45M
-39.1% vs year-ago TTM
Operating cash flow (TTM)
$-238.24M
-35.4% vs year-ago TTM
Free cash flow (TTM)
$-255.10M
-42.2% vs year-ago TTM
EPS (TTM)
$-1.41
-10.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
217.69M
+36.9% vs prior year
Net cash
$592.05M
as of Jun 30, 2026
Operating margin
-603.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OCUL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bedford, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1393434
- Former names
- I-THERAPEUTIX INC (until Jul 2, 2009)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $52.0M | $63.7M | $58.4M | $51.5M | $43.5M |
| Operating income | -$270.0M | -$171.8M | -$82.4M | -$78.7M | -$78.0M |
| Net income | -$265.9M | -$193.5M | -$80.7M | -$71.0M | -$6.6M |
| Diluted EPS | -$1.42 | -$1.22 | -$1.02 | -$0.97 | -$0.98 |
| Operating cash flow | -$204.9M | -$134.7M | -$70.2M | -$59.6M | -$65.5M |
| Free cash flow | -$216.9M | -$136.0M | -$76.3M | -$63.3M | -$66.7M |
| Total assets | $808.1M | $457.9M | $252.1M | $149.3M | $204.9M |
| Total liabilities | $153.7M | $142.6M | $160.9M | $113.9M | $116.9M |
| Stockholders' equity | $654.3M | $315.3M | $91.1M | $35.4M | $88.0M |
| Cash and investments | $737.1M | $392.1M | $195.8M | $102.3M | $164.2M |
| Total debt | $5.6M | $7.3M | $8.5M | $10.3M | $7.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 16, 2026 | Oct 14, 2026 |
| 10-Q | Quarterly report | Aug 3, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 12, 2026 | Jun 10, 2026 |
| 10-Q | Quarterly report | May 5, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 5, 2026 | May 5, 2026 |
All 865 Ocular Therapeutix, Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.